Business
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling,
About this update from Engene Therapeutics Inc.
[{"type":"text","content":"Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations\nBOSTON and MONTREAL, May 2, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or (\"enGene\" or the \"Company\"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.\n\n \n \n \n \n \n \n\n \nThe presentation, \"LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS),\" will be given by Dr. Gordon Brown, Director of the Center for Advanced Therapeutics and Urologic Oncology, Summit Health-South, at 10:30 a.m. CT on Friday, May 3rd during the Paradigm-shifting, Practice-changing Clinical Trials in Urology Plenary Session. The complete dataset from the 12-month follow-up of all patients in the Phase 1 portion of LEGEND will be reported at a future meeting or within a peer-reviewed publication.\n\"I am pleased to present a detailed overview of EG-70 and the pivotal Phase 1/2 LEGEND study. EG-70 is designed to be a practice-changing product that does not require a change in practice for urologists, offering attributes that render it practical for use in community-based and high-volume clinics.\" said Dr. Brown.\nDr. Richard Bryce, enGene's Chief Medical Officer, added: \"The promising initial efficacy and safety data from LEGEND's Phase 1 cohort in high-risk, BCG-unresponsive NMIBC patients with CIS, combined with its ease of handling, simplicity of administration, minimal storage requirements, and lack of post-procedural patient restrictions, demonstrate EG-70's potential to unlock the power of genetic medicine for any and all urologists.\"\n\"EG-70 was rationally designed to be easy to use and meet the needs of patients and urologists alike. As a non-viral, non-infectious, locally delivered genetic medicine, EG-70 is designed to synergistically activate both the innate and adaptive immune responses, be easily reconstituted in water, and requi...